ULURU Inc. is committed to developing and commercializing a broad range of innovative wound care and muco-adhesive film products, based on our patented Nanoflex® and OraDisc™ technologies, with the aim of improving outcomes for patients, health care professionals and providers.
Wound care products maker Uluru (OTCQB:ULUR) expects significant sales growth as its Altrazeal product reaches new markets in the coming year.
Wound care company Uluru (OTCQB:ULUR) has created the “ideal wound product”, according to CEO Kerry Gray, with 2012 set to be a busy year for commercial milestones.
Recent Sector News
U.S. stocks plunged after Federal Reserve chairman Ben Bernanke said quantitative easing may slow down as early as this year. Equities had initially climbed, tanked to session lows and recovered slightly, albeit still treading underwater, in a knee-jerk reaction after the Federal Reserve said it was standing by its monetary policy.
Soligenix (OTCQB:SNGX), a clinical stage biopharmaceutical company, has received fast track designation from U.S. regulatory authorities for its lead compound, for which it is aiming to start phase 2 trials in the second half of this year.
A recent deal in the pharmaceutical sector has shone a light on the fact that Pivotal Therapeutics (CNSX:PVO) (OTCQX:PVTTF) is undervalued, with investors seeing potential for the stock to be valued at up to $500 million, compared to its current market cap of just over $11 million.
Pivotal Therapeutics (OTCQX:PVTTF) (CNSX:PVO), a specialty pharmaceutical company focused on Omega-3 therapies for cardiovascular disease (CVD), has narrowed its first quarter losses as the company's marketing program for its Vascazen product picks up momentum.
A series of American retailers reported a mixed bag of quarterly results after the bell. Sears Holdings (NASDAQ: SHLD) confirmed investor fears, sending the stock tumbling after the company reported a first-quarter loss twice as large as expected. After returning to the black in the fourth quarter following three-straight losing quarters, the Sears department store holding company says it lost $279 million, or $2.63 per diluted share.
Soligenix (OTCQB:SNGX) shares extended their year-to-date gains on Wednesday after the biopharmaceutical company announced that it has been granted a U.S. patent for its Thermovax vaccine thermostabilization technology.
Investors interested in Uluru recently viewed
- Medical Australia Limited (ASX: MLA) Medical devices developed, manufactured and distributed in Australia.
- Tissue Regenix Group (AIM: TRX) Delivering regenerative solutions
- Silence Therapeutics (AIM: SLN) A leader in RNAi therapeutics
- ImmuPharma PLC (AIM: IMM) Drug Discovery & Development to Treat Lupus, Cancer & MRSA
- Sphere Medical (AIM: SPHR) Raising the Standard of Critical Care